AcouSort（ACOU）株式概要AcouSort AB (publish)社は、研究者やライフサイエンス企業向けに、音響流体技術に基づいた生物学的サンプルの自動調製のための製品とソリューションを開発している技術会社です。 詳細ACOU ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長2/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間48.57%増加すると予測されています リスク分析過去5年間で収益は年間3.9%減少しました。 意味のある時価総額がありません ( SEK80M )Swedish市場と比較した過去 3 か月間の株価の変動意味のある収益がありません ( SEK10M )すべてのリスクチェックを見るACOU Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW497,212 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG497,212 investors already sharing narrativesYour Fair ValueSEK Current PriceSEK 3.7970.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-18m73m2016201920222025202620282031Revenue SEK 72.8mEarnings SEK 13.4mAdvancedSet Fair ValueView all narrativesAcouSort AB (publ) 競合他社Subgen AISymbol: OM:SUBGENMarket cap: SEK 73.1mSpago NanomedicalSymbol: OM:SPAGOMarket cap: SEK 93.4mGenetic AnalysisSymbol: NGM:GEANMarket cap: NOK 60.8mAlzinovaSymbol: OM:ALZMarket cap: SEK 76.7m価格と性能株価の高値、安値、推移の概要AcouSort過去の株価現在の株価SEK 3.7952週高値SEK 5.1652週安値SEK 2.03ベータ0.111ヶ月の変化-19.02%3ヶ月変化30.69%1年変化22.26%3年間の変化-74.48%5年間の変化-83.16%IPOからの変化-56.44%最新ニュースReported Earnings • May 28First quarter 2026 earnings released: kr0.11 loss per share (vs kr0.27 loss in 1Q 2025)First quarter 2026 results: kr0.11 loss per share (improved from kr0.27 loss in 1Q 2025). Revenue: kr2.25m (down 14% from 1Q 2025). Net loss: kr2.37m (loss narrowed 41% from 1Q 2025). Revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • May 18AcouSort AB (publ), Annual General Meeting, Jun 18, 2026AcouSort AB (publ), Annual General Meeting, Jun 18, 2026, at 09:00 W. Europe Standard Time. Location: medicon village (building 406), scheelevagen 14, in lund, lund SwedenReported Earnings • Mar 02Full year 2025 earnings released: kr0.64 loss per share (vs kr1.01 loss in FY 2024)Full year 2025 results: kr0.64 loss per share (improved from kr1.01 loss in FY 2024). Revenue: kr10.4m (up 4.0% from FY 2024). Net loss: kr12.2m (loss narrowed 19% from FY 2024). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr56.9m market cap, or US$6.44m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.2m).New Risk • Dec 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr55.2m market cap, or US$5.96m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$5m (kr11m revenue, or US$1.2m).Reported Earnings • Nov 26Third quarter 2025 earnings released: kr0.12 loss per share (vs kr0.25 loss in 3Q 2024)Third quarter 2025 results: kr0.12 loss per share (improved from kr0.25 loss in 3Q 2024). Revenue: kr2.11m (up 12% from 3Q 2024). Net loss: kr2.69m (loss narrowed 29% from 3Q 2024). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.最新情報をもっと見るRecent updatesReported Earnings • May 28First quarter 2026 earnings released: kr0.11 loss per share (vs kr0.27 loss in 1Q 2025)First quarter 2026 results: kr0.11 loss per share (improved from kr0.27 loss in 1Q 2025). Revenue: kr2.25m (down 14% from 1Q 2025). Net loss: kr2.37m (loss narrowed 41% from 1Q 2025). Revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • May 18AcouSort AB (publ), Annual General Meeting, Jun 18, 2026AcouSort AB (publ), Annual General Meeting, Jun 18, 2026, at 09:00 W. Europe Standard Time. Location: medicon village (building 406), scheelevagen 14, in lund, lund SwedenReported Earnings • Mar 02Full year 2025 earnings released: kr0.64 loss per share (vs kr1.01 loss in FY 2024)Full year 2025 results: kr0.64 loss per share (improved from kr1.01 loss in FY 2024). Revenue: kr10.4m (up 4.0% from FY 2024). Net loss: kr12.2m (loss narrowed 19% from FY 2024). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr56.9m market cap, or US$6.44m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.2m).New Risk • Dec 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr55.2m market cap, or US$5.96m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$5m (kr11m revenue, or US$1.2m).Reported Earnings • Nov 26Third quarter 2025 earnings released: kr0.12 loss per share (vs kr0.25 loss in 3Q 2024)Third quarter 2025 results: kr0.12 loss per share (improved from kr0.25 loss in 3Q 2024). Revenue: kr2.11m (up 12% from 3Q 2024). Net loss: kr2.69m (loss narrowed 29% from 3Q 2024). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 27Second quarter 2025 earnings released: kr0.14 loss per share (vs kr0.32 loss in 2Q 2024)Second quarter 2025 results: kr0.14 loss per share (improved from kr0.32 loss in 2Q 2024). Revenue: kr2.88m (up 44% from 2Q 2024). Net loss: kr2.82m (loss narrowed 40% from 2Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 25AcouSort AB (publ) Approves Election of Stefan Blomsterberg and Per Sundkvist as New Board MembersAcouSort AB (publ) at its AGM held on June 25, 2025, approved election of Stefan Blomsterberg and Per Sundkvist as new board members.Reported Earnings • May 30First quarter 2025 earnings released: kr0.27 loss per share (vs kr0.25 loss in 1Q 2024)First quarter 2025 results: kr0.27 loss per share (further deteriorated from kr0.25 loss in 1Q 2024). Revenue: kr2.63m (down 12% from 1Q 2024). Net loss: kr4.02m (loss widened 7.9% from 1Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.お知らせ • May 23AcouSort AB (publ), Annual General Meeting, Jun 25, 2025AcouSort AB (publ), Annual General Meeting, Jun 25, 2025, at 09:00 W. Europe Standard Time. Location: at medicon village building 406, scheelevagen 14, lund SwedenNew Risk • May 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr68.6m market cap, or US$7.02m). Minor Risk Revenue is less than US$5m (kr10m revenue, or US$1.0m).New Risk • May 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr80.4m market cap, or US$8.35m). Minor Risk Revenue is less than US$5m (kr10m revenue, or US$1.0m).お知らせ • May 06AcouSort AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.919048 million.AcouSort AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.919048 million. Security Name: Shares Security Type: Common Stock Securities Offered: 6,229,762 Price\Range: SEK 4 Transaction Features: Rights OfferingNew Risk • Mar 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr20m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (kr10m revenue, or US$988k). Market cap is less than US$10m (kr55.4m market cap, or US$5.46m).New Risk • Feb 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr102.1m (US$9.59m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr8.0m revenue, or US$754k). Market cap is less than US$10m (kr102.1m market cap, or US$9.59m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).お知らせ • Feb 14+ 3 more updatesAcouSort AB (publ) to Report Q1, 2025 Results on May 28, 2025AcouSort AB (publ) announced that they will report Q1, 2025 results on May 28, 2025Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Board Member Katherine Flagg was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr8.0m revenue, or US$731k). Minor Risk Market cap is less than US$100m (kr176.2m market cap, or US$16.1m).Reported Earnings • Nov 28Third quarter 2024 earnings released: kr0.25 loss per share (vs kr0.33 loss in 3Q 2023)Third quarter 2024 results: kr0.25 loss per share (improved from kr0.33 loss in 3Q 2023). Revenue: kr1.88m (down 13% from 3Q 2023). Net loss: kr3.81m (loss narrowed 12% from 3Q 2023). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 29Second quarter 2024 earnings released: kr0.32 loss per share (vs kr0.24 loss in 2Q 2023)Second quarter 2024 results: kr0.32 loss per share (further deteriorated from kr0.24 loss in 2Q 2023). Revenue: kr1.99m (down 41% from 2Q 2023). Net loss: kr4.71m (loss widened 48% from 2Q 2023). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.Reported Earnings • May 23First quarter 2024 earnings released: kr0.25 loss per share (vs kr0.23 loss in 1Q 2023)First quarter 2024 results: kr0.25 loss per share (further deteriorated from kr0.23 loss in 1Q 2023). Revenue: kr2.97m (down 23% from 1Q 2023). Net loss: kr3.73m (loss widened 23% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.お知らせ • May 03AcouSort AB (publ) to Present Two Posters Highlighting the Value of Acoustofluidics Sample PreparationAcouSort AB (publ) will exhibit and present at CYTO 2024 - demonstrating the benefits of acoustic sample preparation for flow cytometry applications. CYTO 2024, the 37th annual Congress of the International Society for the Advancement of Cytometry is an international conference on the many facets of cytometry science and engineering. In line with the company's focus on novel opportunities within cytometry, AcouSort will participate in the conference to present its innovative solutions for sample preparation and the vital role they can play to improve flow cytometry outcomes. AcouSort has also been selected to present two posters highlighting the value of acoustofluidics sample preparation. The first poster is presented by Dr Vera A Tang of University of Ottawa. During the spring of 2024, AcouSort has collaborated with Dr Tang and her team on the development of a new method for isolation of cells from dissociation tissue using the AcouWash. The poster describes how the AcouWash system is used to purify dissociation tissue samples and efficiently remove debris and dead cells from the target cells, something that is very difficult to do with other techniques. Dr Tang's main conclusions are that sample preparation using the AcouWash system offers a low-cost, gentle, and effective way to ensure that downstream analysis is performed on high quality viable samples. The second poster presents AcouSort's in-house work on high throughput cell wash and show new data on efficient and gentle cell wash at flowrates up to 5 mL/minute combined with a 5x up-concentration. By using acoustic cell wash, contaminants can be efficiently removed from the cells in a one-step process while retaining more than 98% of the cells. Proliferation studies also show that the AcouWash technology is very gentle to the cells and that cell proliferation after acoustic processing is the same as for unprocessed samples. The results presented in the poster is a great example on how acoustic sorting can be rapid, efficient, and gentle to the cells, combining several sample preparation steps into one.Reported Earnings • Apr 02Full year 2023 earnings released: kr1.29 loss per share (vs kr1.04 loss in FY 2022)Full year 2023 results: kr1.29 loss per share (further deteriorated from kr1.04 loss in FY 2022). Revenue: kr10.6m (up 23% from FY 2022). Net loss: kr17.1m (loss widened 24% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.New Risk • Mar 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr13m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (kr12m revenue, or US$1.1m). Market cap is less than US$100m (kr183.3m market cap, or US$17.1m).Recent Insider Transactions • Mar 04Founder & Independent Director recently bought kr52k worth of stockOn the 1st of March, Stefan Scheding bought around 4k shares on-market at roughly kr12.66 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months.お知らせ • Feb 28+ 5 more updatesAcouSort AB (publ) to Report Q3, 2024 Results on Nov 27, 2024AcouSort AB (publ) announced that they will report Q3, 2024 results on Nov 27, 2024New Risk • Dec 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr13m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Revenue is less than US$5m (kr12m revenue, or US$1.2m). Market cap is less than US$100m (kr228.6m market cap, or US$22.0m).お知らせ • Dec 02AcouSort AB (publ) has completed a Composite Units Offering.AcouSort AB (publ) has completed a Composite Units Offering. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 515,526 Price\Range: SEK 45 Transaction Features: Rights OfferingReported Earnings • Nov 08Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.32 loss in 3Q 2022)Third quarter 2023 results: kr0.33 loss per share (further deteriorated from kr0.32 loss in 3Q 2022). Revenue: kr2.16m (up 63% from 3Q 2022). Net loss: kr4.30m (loss widened 2.0% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.New Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (kr11m revenue, or US$1.0m). Market cap is less than US$100m (kr211.2m market cap, or US$19.3m).お知らせ • Nov 07AcouSort AB (publ) to Report Q4, 2023 Results on Feb 28, 2024AcouSort AB (publ) announced that they will report Q4, 2023 results on Feb 28, 2024New Risk • Aug 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (kr11m revenue, or US$1.0m). Market cap is less than US$100m (kr235.0m market cap, or US$21.2m).New Risk • Aug 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (kr9.7m revenue, or US$899k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (kr231.0m market cap, or US$21.3m).分析記事 • Aug 15AcouSort (STO:ACOU) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Jun 17AcouSort AB (publ) Recruits Henrik Johansson to the Position as Director of Research and TechnologyAcouSort AB (publ) has recruited Henrik Johansson to the position as Director of Research and Technology. Henrik has significant experience from startup environment within the biotech space as well as from R&D management roles at Agilent and PerkinElmer. Going forward, he will play a key role in the further development of the company's technology portfolio. As Director of Research and Technology, Henrik will be responsible for the company's Research projects. Primary focus will be on managing research activities aimed at further developing and applying the company's core technology to address unmet needs identified in clinical research and practice. Henrik will also be responsible for identifying new technology frontiers that enables development of products. Henrik has extensive knowledge of developing novel products based on proprietary technology and experience of leading product development projects from idea stage to product launch.Reported Earnings • Jun 01First quarter 2023 earnings released: kr0.23 loss per share (vs kr0.20 loss in 1Q 2022)First quarter 2023 results: kr0.23 loss per share (further deteriorated from kr0.20 loss in 1Q 2022). Revenue: kr3.85m (up 43% from 1Q 2022). Net loss: kr3.04m (loss widened 16% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.お知らせ • May 23AcouSort AB (publ) Launches Next Generation AcouTrap at CYTO 2023AcouSort launches next generation AcouTrap at CYTO 2023. CYTO is organized by the International Society for the Advancement of Cytometry and attended by leading researchers and instrumentation providers within flow cytometry. This year, AcouSort will use the conference to launch the new and much improved AcouTrap system. The conference is held in Montréal, Canada, May 20-24. The new AcouTrap 3 system comes with improved design and an updated and intuitive software graphical user interface (GUI), which simplifies user workflows. The new design and new software are based on customer feedback from AcouSort's last generation of AcouTrap. Along with the upgrades to the AcouTrap system, AcouSort also presents two new trapping units with improved performance. The smaller unit has a capacity of up to 100,000 cells and is d esigned for minute samples and rare cells, while the enhanced unit has higher throughput and can handle up to 0.5 million cells. Both units allow for gentle, automated handling with minimal cell loss .Reported Earnings • Feb 22Full year 2022 earnings released: kr0.98 loss per share (vs kr0.92 loss in FY 2021)Full year 2022 results: kr0.98 loss per share (further deteriorated from kr0.92 loss in FY 2021). Revenue: kr8.59m (up 44% from FY 2021). Net loss: kr12.9m (loss widened 5.8% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Recent Insider Transactions • Dec 06Founder & Independent Director recently bought kr68k worth of stockOn the 2nd of December, Thomas Laurell bought around 4k shares on-market at roughly kr19.33 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Thomas' only on-market trade for the last 12 months.分析記事 • Nov 25Will AcouSort (STO:ACOU) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Reported Earnings • Nov 24Third quarter 2022 earnings released: kr0.32 loss per share (vs kr0.30 loss in 3Q 2021)Third quarter 2022 results: kr0.32 loss per share (further deteriorated from kr0.30 loss in 3Q 2021). Revenue: kr1.33m (up 79% from 3Q 2021). Net loss: kr4.22m (loss widened 22% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.Reported Earnings • Aug 24Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.31 loss in 2Q 2021)Second quarter 2022 results: kr0.31 loss per share (vs kr0.31 loss in 2Q 2021). Revenue: kr1.81m (up 51% from 2Q 2021). Net loss: kr4.03m (loss widened 16% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.分析記事 • Aug 09We Think AcouSort (STO:ACOU) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • May 19First quarter 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in 1Q 2021)First quarter 2022 results: kr0.20 loss per share (down from kr0.15 loss in 1Q 2021). Revenue: kr2.69m (down 4.1% from 1Q 2021). Net loss: kr2.61m (loss widened 55% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.Recent Insider Transactions • Mar 05Founder & Independent Director recently bought kr95k worth of stockOn the 3rd of March, Stefan Scheding bought around 5k shares on-market at roughly kr19.00 per share. This was the largest purchase by an insider in the last 3 months. Stefan has been a buyer over the last 12 months, purchasing a net total of kr120k worth in shares.分析記事 • Mar 02We're Hopeful That AcouSort (STO:ACOU) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Reported Earnings • Feb 25Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.92 loss per share (down from kr0.70 loss in FY 2020). Revenue: kr5.96m (up 21% from FY 2020). Net loss: kr12.2m (loss widened 53% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 36% per year, which means it is well ahead of earnings.Reported Earnings • Nov 25Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: kr0.31 loss per share (down from kr0.20 loss in 3Q 2020). Revenue: kr739.0k (up 262% from 3Q 2020). Net loss: kr3.45m (loss widened 56% from 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 26Second quarter 2021 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr1.20m (down 17% from 2Q 2020). Net loss: kr3.48m (loss widened 160% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 28First quarter 2021 earnings released: kr0.15 loss per share (vs kr0.10 loss in 1Q 2020)The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: kr2.80m (up 34% from 1Q 2020). Net loss: kr1.69m (loss widened 65% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • May 03We're Not Very Worried About AcouSort's (STO:ACOU) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. Indeed, AcouSort ( STO:ACOU ) stock is...Reported Earnings • Feb 25Full year 2020 earnings released: kr0.70 loss per share (vs kr0.96 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr6.82m (up 268% from FY 2019). Net loss: kr7.98m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 29AcouSort AB Enters Collaboration Agreement with Belgian Diagnostics CompanyAcouSort AB has entered a partnership with a Belgian diagnostics company that develops innovative products for point-of-care testing. Together, the companies will develop a test platform based on AcouSort's technology to be used in the Belgian company's product development. The Belgium-based company is developing a platform for point-of-care diagnostics based on whole blood, initially focusing on analysis of blood cells. In the long term, there are plans to develop the system to be able to analyze other fractions of blood samples. With the jointly developed test platform, the Belgian company will evaluate if AcouSort's technology for integrated blood separation can improve their system's measurement performance.分析記事 • Jan 18We Think AcouSort (STO:ACOU) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, AcouSort...お知らせ • Jan 17Physio-Tech Co.,Ltd. acquired AcouTrap system from AcouSort AB (publ) (OM:ACOU).Physio-Tech Co.,Ltd. acquired AcouTrap system from AcouSort AB (publ) (OM:ACOU) on January 15, 2021. Physio-Tech Co.,Ltd. completed the acquisition of AcouTrap system from AcouSort AB (publ) (OM:ACOU) on January 15, 2021.Is New 90 Day High Low • Jan 14New 90-day high: kr26.90The company is up 76% from its price of kr15.25 on 15 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period.Is New 90 Day High Low • Dec 28New 90-day high: kr22.30The company is up 63% from its price of kr13.70 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 12% over the same period.Is New 90 Day High Low • Dec 04New 90-day high: kr21.80The company is up 124% from its price of kr9.74 on 04 September 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period.Reported Earnings • Nov 28Third quarter 2020 earnings released: kr0.20 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: kr662.0k (up 25% from 3Q 2019). Net loss: kr2.21m (loss widened 27% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Nov 11New 90-day high: kr19.25The company is up 102% from its price of kr9.52 on 13 August 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period.Is New 90 Day High Low • Oct 07New 90-day high: kr16.85The company is up 63% from its price of kr10.35 on 09 July 2020. The Swedish market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.Is New 90 Day High Low • Sep 22New 90-day high: kr12.40The company is up 22% from its price of kr10.15 on 24 June 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period.株主還元ACOUSE BiotechsSE 市場7D-0.8%3.5%3.0%1Y22.3%31.2%13.3%株主還元を見る業界別リターン: ACOU過去 1 年間で31.2 % の収益を上げたSwedish Biotechs業界を下回りました。リターン対市場: ACOU過去 1 年間で13.3 % の収益を上げたSwedish市場を上回りました。価格変動Is ACOU's price volatile compared to industry and market?ACOU volatilityACOU Average Weekly Movement11.0%Biotechs Industry Average Movement9.7%Market Average Movement6.1%10% most volatile stocks in SE Market13.0%10% least volatile stocks in SE Market3.4%安定した株価: ACOUの株価は、 Swedish市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ACOUの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてSwedishの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201011Torsten Freltoftwww.acousort.comAcouSort AB (publish)は、研究者やライフサイエンス企業向けに、音響流体技術に基づく生物学的サンプルの自動調製のための製品とソリューションを開発しているテクノロジー企業である。様々な培地から細胞、細胞外小胞、バクテリア、ウイルスをサンプル調製する卓上研究機器AcouTrap、全血サンプルから血漿のインライン分析を可能にする統合血漿分離モジュールAcouPlasma、様々なサンプルから標的細胞をラベルフリーで分離する卓上研究機器AcouWashを提供している。同社は、細胞治療を開発するために世界的なライフサイエンス企業と共同研究契約を結んでいる。AcouSort ABとBio-ReCell Ltd.は、脂肪組織から幹細胞や免疫細胞を自動洗浄・分離するシステムを共同開発する意向書を締結したと発表した。AcouSort AB（publish）は2010年に設立され、スウェーデンのルンドに本拠を置く。もっと見るAcouSort AB (publ) 基礎のまとめAcouSort の収益と売上を時価総額と比較するとどうか。ACOU 基礎統計学時価総額SEK 80.21m収益（TTM）-SEK 10.50m売上高(TTM)SEK 10.05m8.0xP/Sレシオ-7.6xPER（株価収益率ACOU は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ACOU 損益計算書（TTM）収益SEK 10.05m売上原価SEK 148.00k売上総利益SEK 9.90mその他の費用SEK 20.40m収益-SEK 10.50m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.50グロス・マージン98.53%純利益率-104.46%有利子負債／自己資本比率0%ACOU の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/06 12:58終値2026/07/03 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AcouSort AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Gustaf MeyerRedeyeJohn WestborgRedeye
Reported Earnings • May 28First quarter 2026 earnings released: kr0.11 loss per share (vs kr0.27 loss in 1Q 2025)First quarter 2026 results: kr0.11 loss per share (improved from kr0.27 loss in 1Q 2025). Revenue: kr2.25m (down 14% from 1Q 2025). Net loss: kr2.37m (loss narrowed 41% from 1Q 2025). Revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • May 18AcouSort AB (publ), Annual General Meeting, Jun 18, 2026AcouSort AB (publ), Annual General Meeting, Jun 18, 2026, at 09:00 W. Europe Standard Time. Location: medicon village (building 406), scheelevagen 14, in lund, lund Sweden
Reported Earnings • Mar 02Full year 2025 earnings released: kr0.64 loss per share (vs kr1.01 loss in FY 2024)Full year 2025 results: kr0.64 loss per share (improved from kr1.01 loss in FY 2024). Revenue: kr10.4m (up 4.0% from FY 2024). Net loss: kr12.2m (loss narrowed 19% from FY 2024). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr56.9m market cap, or US$6.44m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.2m).
New Risk • Dec 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr55.2m market cap, or US$5.96m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$5m (kr11m revenue, or US$1.2m).
Reported Earnings • Nov 26Third quarter 2025 earnings released: kr0.12 loss per share (vs kr0.25 loss in 3Q 2024)Third quarter 2025 results: kr0.12 loss per share (improved from kr0.25 loss in 3Q 2024). Revenue: kr2.11m (up 12% from 3Q 2024). Net loss: kr2.69m (loss narrowed 29% from 3Q 2024). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
Reported Earnings • May 28First quarter 2026 earnings released: kr0.11 loss per share (vs kr0.27 loss in 1Q 2025)First quarter 2026 results: kr0.11 loss per share (improved from kr0.27 loss in 1Q 2025). Revenue: kr2.25m (down 14% from 1Q 2025). Net loss: kr2.37m (loss narrowed 41% from 1Q 2025). Revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • May 18AcouSort AB (publ), Annual General Meeting, Jun 18, 2026AcouSort AB (publ), Annual General Meeting, Jun 18, 2026, at 09:00 W. Europe Standard Time. Location: medicon village (building 406), scheelevagen 14, in lund, lund Sweden
Reported Earnings • Mar 02Full year 2025 earnings released: kr0.64 loss per share (vs kr1.01 loss in FY 2024)Full year 2025 results: kr0.64 loss per share (improved from kr1.01 loss in FY 2024). Revenue: kr10.4m (up 4.0% from FY 2024). Net loss: kr12.2m (loss narrowed 19% from FY 2024). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr56.9m market cap, or US$6.44m). Minor Risk Revenue is less than US$5m (kr11m revenue, or US$1.2m).
New Risk • Dec 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr16m free cash flow). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr55.2m market cap, or US$5.96m). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Revenue is less than US$5m (kr11m revenue, or US$1.2m).
Reported Earnings • Nov 26Third quarter 2025 earnings released: kr0.12 loss per share (vs kr0.25 loss in 3Q 2024)Third quarter 2025 results: kr0.12 loss per share (improved from kr0.25 loss in 3Q 2024). Revenue: kr2.11m (up 12% from 3Q 2024). Net loss: kr2.69m (loss narrowed 29% from 3Q 2024). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 27Second quarter 2025 earnings released: kr0.14 loss per share (vs kr0.32 loss in 2Q 2024)Second quarter 2025 results: kr0.14 loss per share (improved from kr0.32 loss in 2Q 2024). Revenue: kr2.88m (up 44% from 2Q 2024). Net loss: kr2.82m (loss narrowed 40% from 2Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 25AcouSort AB (publ) Approves Election of Stefan Blomsterberg and Per Sundkvist as New Board MembersAcouSort AB (publ) at its AGM held on June 25, 2025, approved election of Stefan Blomsterberg and Per Sundkvist as new board members.
Reported Earnings • May 30First quarter 2025 earnings released: kr0.27 loss per share (vs kr0.25 loss in 1Q 2024)First quarter 2025 results: kr0.27 loss per share (further deteriorated from kr0.25 loss in 1Q 2024). Revenue: kr2.63m (down 12% from 1Q 2024). Net loss: kr4.02m (loss widened 7.9% from 1Q 2024). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.
お知らせ • May 23AcouSort AB (publ), Annual General Meeting, Jun 25, 2025AcouSort AB (publ), Annual General Meeting, Jun 25, 2025, at 09:00 W. Europe Standard Time. Location: at medicon village building 406, scheelevagen 14, lund Sweden
New Risk • May 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr68.6m market cap, or US$7.02m). Minor Risk Revenue is less than US$5m (kr10m revenue, or US$1.0m).
New Risk • May 06New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (kr80.4m market cap, or US$8.35m). Minor Risk Revenue is less than US$5m (kr10m revenue, or US$1.0m).
お知らせ • May 06AcouSort AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.919048 million.AcouSort AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 24.919048 million. Security Name: Shares Security Type: Common Stock Securities Offered: 6,229,762 Price\Range: SEK 4 Transaction Features: Rights Offering
New Risk • Mar 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr20m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (kr10m revenue, or US$988k). Market cap is less than US$10m (kr55.4m market cap, or US$5.46m).
New Risk • Feb 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr102.1m (US$9.59m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr8.0m revenue, or US$754k). Market cap is less than US$10m (kr102.1m market cap, or US$9.59m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
お知らせ • Feb 14+ 3 more updatesAcouSort AB (publ) to Report Q1, 2025 Results on May 28, 2025AcouSort AB (publ) announced that they will report Q1, 2025 results on May 28, 2025
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Board Member Katherine Flagg was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr19m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m (kr8.0m revenue, or US$731k). Minor Risk Market cap is less than US$100m (kr176.2m market cap, or US$16.1m).
Reported Earnings • Nov 28Third quarter 2024 earnings released: kr0.25 loss per share (vs kr0.33 loss in 3Q 2023)Third quarter 2024 results: kr0.25 loss per share (improved from kr0.33 loss in 3Q 2023). Revenue: kr1.88m (down 13% from 3Q 2023). Net loss: kr3.81m (loss narrowed 12% from 3Q 2023). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 29Second quarter 2024 earnings released: kr0.32 loss per share (vs kr0.24 loss in 2Q 2023)Second quarter 2024 results: kr0.32 loss per share (further deteriorated from kr0.24 loss in 2Q 2023). Revenue: kr1.99m (down 41% from 2Q 2023). Net loss: kr4.71m (loss widened 48% from 2Q 2023). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 12% per year whereas the company’s share price has fallen by 13% per year.
Reported Earnings • May 23First quarter 2024 earnings released: kr0.25 loss per share (vs kr0.23 loss in 1Q 2023)First quarter 2024 results: kr0.25 loss per share (further deteriorated from kr0.23 loss in 1Q 2023). Revenue: kr2.97m (down 23% from 1Q 2023). Net loss: kr3.73m (loss widened 23% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
お知らせ • May 03AcouSort AB (publ) to Present Two Posters Highlighting the Value of Acoustofluidics Sample PreparationAcouSort AB (publ) will exhibit and present at CYTO 2024 - demonstrating the benefits of acoustic sample preparation for flow cytometry applications. CYTO 2024, the 37th annual Congress of the International Society for the Advancement of Cytometry is an international conference on the many facets of cytometry science and engineering. In line with the company's focus on novel opportunities within cytometry, AcouSort will participate in the conference to present its innovative solutions for sample preparation and the vital role they can play to improve flow cytometry outcomes. AcouSort has also been selected to present two posters highlighting the value of acoustofluidics sample preparation. The first poster is presented by Dr Vera A Tang of University of Ottawa. During the spring of 2024, AcouSort has collaborated with Dr Tang and her team on the development of a new method for isolation of cells from dissociation tissue using the AcouWash. The poster describes how the AcouWash system is used to purify dissociation tissue samples and efficiently remove debris and dead cells from the target cells, something that is very difficult to do with other techniques. Dr Tang's main conclusions are that sample preparation using the AcouWash system offers a low-cost, gentle, and effective way to ensure that downstream analysis is performed on high quality viable samples. The second poster presents AcouSort's in-house work on high throughput cell wash and show new data on efficient and gentle cell wash at flowrates up to 5 mL/minute combined with a 5x up-concentration. By using acoustic cell wash, contaminants can be efficiently removed from the cells in a one-step process while retaining more than 98% of the cells. Proliferation studies also show that the AcouWash technology is very gentle to the cells and that cell proliferation after acoustic processing is the same as for unprocessed samples. The results presented in the poster is a great example on how acoustic sorting can be rapid, efficient, and gentle to the cells, combining several sample preparation steps into one.
Reported Earnings • Apr 02Full year 2023 earnings released: kr1.29 loss per share (vs kr1.04 loss in FY 2022)Full year 2023 results: kr1.29 loss per share (further deteriorated from kr1.04 loss in FY 2022). Revenue: kr10.6m (up 23% from FY 2022). Net loss: kr17.1m (loss widened 24% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
New Risk • Mar 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr13m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (kr12m revenue, or US$1.1m). Market cap is less than US$100m (kr183.3m market cap, or US$17.1m).
Recent Insider Transactions • Mar 04Founder & Independent Director recently bought kr52k worth of stockOn the 1st of March, Stefan Scheding bought around 4k shares on-market at roughly kr12.66 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Stefan's only on-market trade for the last 12 months.
お知らせ • Feb 28+ 5 more updatesAcouSort AB (publ) to Report Q3, 2024 Results on Nov 27, 2024AcouSort AB (publ) announced that they will report Q3, 2024 results on Nov 27, 2024
New Risk • Dec 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr13m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (12% increase in shares outstanding). Revenue is less than US$5m (kr12m revenue, or US$1.2m). Market cap is less than US$100m (kr228.6m market cap, or US$22.0m).
お知らせ • Dec 02AcouSort AB (publ) has completed a Composite Units Offering.AcouSort AB (publ) has completed a Composite Units Offering. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 515,526 Price\Range: SEK 45 Transaction Features: Rights Offering
Reported Earnings • Nov 08Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.32 loss in 3Q 2022)Third quarter 2023 results: kr0.33 loss per share (further deteriorated from kr0.32 loss in 3Q 2022). Revenue: kr2.16m (up 63% from 3Q 2022). Net loss: kr4.30m (loss widened 2.0% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
New Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (kr11m revenue, or US$1.0m). Market cap is less than US$100m (kr211.2m market cap, or US$19.3m).
お知らせ • Nov 07AcouSort AB (publ) to Report Q4, 2023 Results on Feb 28, 2024AcouSort AB (publ) announced that they will report Q4, 2023 results on Feb 28, 2024
New Risk • Aug 25New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr12m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (kr11m revenue, or US$1.0m). Market cap is less than US$100m (kr235.0m market cap, or US$21.2m).
New Risk • Aug 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (kr9.7m revenue, or US$899k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (kr231.0m market cap, or US$21.3m).
分析記事 • Aug 15AcouSort (STO:ACOU) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Jun 17AcouSort AB (publ) Recruits Henrik Johansson to the Position as Director of Research and TechnologyAcouSort AB (publ) has recruited Henrik Johansson to the position as Director of Research and Technology. Henrik has significant experience from startup environment within the biotech space as well as from R&D management roles at Agilent and PerkinElmer. Going forward, he will play a key role in the further development of the company's technology portfolio. As Director of Research and Technology, Henrik will be responsible for the company's Research projects. Primary focus will be on managing research activities aimed at further developing and applying the company's core technology to address unmet needs identified in clinical research and practice. Henrik will also be responsible for identifying new technology frontiers that enables development of products. Henrik has extensive knowledge of developing novel products based on proprietary technology and experience of leading product development projects from idea stage to product launch.
Reported Earnings • Jun 01First quarter 2023 earnings released: kr0.23 loss per share (vs kr0.20 loss in 1Q 2022)First quarter 2023 results: kr0.23 loss per share (further deteriorated from kr0.20 loss in 1Q 2022). Revenue: kr3.85m (up 43% from 1Q 2022). Net loss: kr3.04m (loss widened 16% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
お知らせ • May 23AcouSort AB (publ) Launches Next Generation AcouTrap at CYTO 2023AcouSort launches next generation AcouTrap at CYTO 2023. CYTO is organized by the International Society for the Advancement of Cytometry and attended by leading researchers and instrumentation providers within flow cytometry. This year, AcouSort will use the conference to launch the new and much improved AcouTrap system. The conference is held in Montréal, Canada, May 20-24. The new AcouTrap 3 system comes with improved design and an updated and intuitive software graphical user interface (GUI), which simplifies user workflows. The new design and new software are based on customer feedback from AcouSort's last generation of AcouTrap. Along with the upgrades to the AcouTrap system, AcouSort also presents two new trapping units with improved performance. The smaller unit has a capacity of up to 100,000 cells and is d esigned for minute samples and rare cells, while the enhanced unit has higher throughput and can handle up to 0.5 million cells. Both units allow for gentle, automated handling with minimal cell loss .
Reported Earnings • Feb 22Full year 2022 earnings released: kr0.98 loss per share (vs kr0.92 loss in FY 2021)Full year 2022 results: kr0.98 loss per share (further deteriorated from kr0.92 loss in FY 2021). Revenue: kr8.59m (up 44% from FY 2021). Net loss: kr12.9m (loss widened 5.8% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Recent Insider Transactions • Dec 06Founder & Independent Director recently bought kr68k worth of stockOn the 2nd of December, Thomas Laurell bought around 4k shares on-market at roughly kr19.33 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Thomas' only on-market trade for the last 12 months.
分析記事 • Nov 25Will AcouSort (STO:ACOU) Spend Its Cash Wisely?We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Reported Earnings • Nov 24Third quarter 2022 earnings released: kr0.32 loss per share (vs kr0.30 loss in 3Q 2021)Third quarter 2022 results: kr0.32 loss per share (further deteriorated from kr0.30 loss in 3Q 2021). Revenue: kr1.33m (up 79% from 3Q 2021). Net loss: kr4.22m (loss widened 22% from 3Q 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
Reported Earnings • Aug 24Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.31 loss in 2Q 2021)Second quarter 2022 results: kr0.31 loss per share (vs kr0.31 loss in 2Q 2021). Revenue: kr1.81m (up 51% from 2Q 2021). Net loss: kr4.03m (loss widened 16% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
分析記事 • Aug 09We Think AcouSort (STO:ACOU) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • May 19First quarter 2022 earnings released: kr0.20 loss per share (vs kr0.15 loss in 1Q 2021)First quarter 2022 results: kr0.20 loss per share (down from kr0.15 loss in 1Q 2021). Revenue: kr2.69m (down 4.1% from 1Q 2021). Net loss: kr2.61m (loss widened 55% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
Recent Insider Transactions • Mar 05Founder & Independent Director recently bought kr95k worth of stockOn the 3rd of March, Stefan Scheding bought around 5k shares on-market at roughly kr19.00 per share. This was the largest purchase by an insider in the last 3 months. Stefan has been a buyer over the last 12 months, purchasing a net total of kr120k worth in shares.
分析記事 • Mar 02We're Hopeful That AcouSort (STO:ACOU) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Reported Earnings • Feb 25Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.92 loss per share (down from kr0.70 loss in FY 2020). Revenue: kr5.96m (up 21% from FY 2020). Net loss: kr12.2m (loss widened 53% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 36% per year, which means it is well ahead of earnings.
Reported Earnings • Nov 25Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: kr0.31 loss per share (down from kr0.20 loss in 3Q 2020). Revenue: kr739.0k (up 262% from 3Q 2020). Net loss: kr3.45m (loss widened 56% from 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 26Second quarter 2021 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2020)The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr1.20m (down 17% from 2Q 2020). Net loss: kr3.48m (loss widened 160% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 36% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 28First quarter 2021 earnings released: kr0.15 loss per share (vs kr0.10 loss in 1Q 2020)The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: kr2.80m (up 34% from 1Q 2020). Net loss: kr1.69m (loss widened 65% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • May 03We're Not Very Worried About AcouSort's (STO:ACOU) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. Indeed, AcouSort ( STO:ACOU ) stock is...
Reported Earnings • Feb 25Full year 2020 earnings released: kr0.70 loss per share (vs kr0.96 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr6.82m (up 268% from FY 2019). Net loss: kr7.98m (loss narrowed 17% from FY 2019). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 29AcouSort AB Enters Collaboration Agreement with Belgian Diagnostics CompanyAcouSort AB has entered a partnership with a Belgian diagnostics company that develops innovative products for point-of-care testing. Together, the companies will develop a test platform based on AcouSort's technology to be used in the Belgian company's product development. The Belgium-based company is developing a platform for point-of-care diagnostics based on whole blood, initially focusing on analysis of blood cells. In the long term, there are plans to develop the system to be able to analyze other fractions of blood samples. With the jointly developed test platform, the Belgian company will evaluate if AcouSort's technology for integrated blood separation can improve their system's measurement performance.
分析記事 • Jan 18We Think AcouSort (STO:ACOU) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, AcouSort...
お知らせ • Jan 17Physio-Tech Co.,Ltd. acquired AcouTrap system from AcouSort AB (publ) (OM:ACOU).Physio-Tech Co.,Ltd. acquired AcouTrap system from AcouSort AB (publ) (OM:ACOU) on January 15, 2021. Physio-Tech Co.,Ltd. completed the acquisition of AcouTrap system from AcouSort AB (publ) (OM:ACOU) on January 15, 2021.
Is New 90 Day High Low • Jan 14New 90-day high: kr26.90The company is up 76% from its price of kr15.25 on 15 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Dec 28New 90-day high: kr22.30The company is up 63% from its price of kr13.70 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 12% over the same period.
Is New 90 Day High Low • Dec 04New 90-day high: kr21.80The company is up 124% from its price of kr9.74 on 04 September 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 1.0% over the same period.
Reported Earnings • Nov 28Third quarter 2020 earnings released: kr0.20 loss per shareThe company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: kr662.0k (up 25% from 3Q 2019). Net loss: kr2.21m (loss widened 27% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Nov 11New 90-day high: kr19.25The company is up 102% from its price of kr9.52 on 13 August 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Oct 07New 90-day high: kr16.85The company is up 63% from its price of kr10.35 on 09 July 2020. The Swedish market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.
Is New 90 Day High Low • Sep 22New 90-day high: kr12.40The company is up 22% from its price of kr10.15 on 24 June 2020. The Swedish market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 19% over the same period.
